Medical Microinstruments Raised $125 Million

The company plans to fund commercial expansion and new clinical trials for its robotic surgical platform.

Updated on Oct. 8, 2026 in Healthcare

A high-tech robotic surgical arm with intricate metallic joints positioned in a pristine, bright medical suite. — Medical Microinstruments secured $125 million in Series D funding led by BioStar Capital to support global expansion and clinical trials for its robotic surgical platform. AI Illustration. Upload story photo >

Live Poll

Do you trust that new medical robotics technologies will improve long-term patient care and outcomes?

Medical Microinstruments secured $125 million in a Series D funding round led by BioStar Capital. The capital will support global market expansion and clinical trials for the company's robotic microsurgery system.

Why it matters

The funding aims to increase patient access to robotic microsurgery by scaling commercial operations and advancing clinical research. These resources will also support the development of future digital surgery capabilities.

The company has 50 Symani Surgical Systems currently installed worldwide and has successfully completed 3,500 complex microsurgical procedures. The system utilizes wristed microinstruments equipped with motion-scaling and tremor-reduction technologies.

The players

Medical Microinstruments

This company develops robotic technology for microsurgical procedures and was founded in 2015 near Pisa, Italy.

BioStar Capital

This investment firm led the latest Series D funding round for Medical Microinstruments.

S3 Ventures

This firm participated as a new investor in the latest financing round.

Angelini Ventures

This organization joined as a new investor during the recent funding effort.

The details

Medical Microinstruments plans to invest the new capital into clinical trials, including the REMIND study, and the development of energy instruments. The firm, founded in 2015, currently holds FDA authorization in the U.S. and a CE Mark in Europe for its surgical technology.

Medical Microinstruments was founded in 2015.
The Series D funding round was announced on October 8, 2026.

Market Landscape

This funding reflects the broader industry shift toward integrating robotic platforms into complex surgical care to improve precision. It positions Medical Microinstruments to scale its operations against other providers in the growing robotic surgery sector.

Patients may see increased availability of robotic-assisted procedures as the company expands its commercial footprint in the U.S. and Europe. The funding ensures that the Symani Surgical System remains a supported platform for hospitals adopting new digital surgery tools.

The takeaway

The infusion of capital allows Medical Microinstruments to transition from a growing startup to a larger commercial player in the surgical tech space. Prospective patients and hospital administrators should monitor future clinical trial results to gauge the long-term efficacy of these systems.